Privium Fund Management B.V. Takes Position in Hims & Hers Health, Inc. $HIMS

Key Points

• Privium Fund Management B.V. purchased 22,000 shares of Hims & Hers Health, Inc., valued at approximately $1,097,000, during the second quarter.
• Insider trading was notable, with CFO Oluyemi Okupe selling 145,000 shares and reducing their position by 52.92%.
• Hims & Hers Health's stock has a consensus rating of "Reduce" with an average target price of $38.92, despite two analysts rating it as a "Buy."

Privium Fund Management B.V. purchased a new position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 22,000 shares of the company's stock, valued at approximately $1,097,000.

A number of other hedge funds also recently made changes to their positions in HIMS. Securian Asset Management Inc. increased its stake in Hims & Hers Health by 2.8% in the second quarter. Securian Asset Management Inc. now owns 14,931 shares of the company's stock valued at $744,000 after acquiring an additional 411 shares during the last quarter. Pinnacle Wealth Management LLC lifted its stake in Hims & Hers Health by 198.7% during the second quarter. Pinnacle Wealth Management LLC now owns 44,650 shares of the company's stock worth $2,226,000 after purchasing an additional 29,704 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Hims & Hers Health in the 2nd quarter worth about $1,266,000. Stratos Wealth Partners LTD. bought a new position in shares of Hims & Hers Health during the 2nd quarter valued at about $236,000. Finally, WealthPlan Investment Management LLC raised its holdings in shares of Hims & Hers Health by 2.6% during the 2nd quarter. WealthPlan Investment Management LLC now owns 16,404 shares of the company's stock valued at $818,000 after buying an additional 410 shares in the last quarter. 63.52% of the stock is owned by institutional investors.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 145,000 shares of the company's stock in a transaction on Monday, September 15th. The shares were sold at an average price of $55.35, for a total value of $8,025,750.00. Following the completion of the transaction, the chief financial officer directly owned 128,984 shares in the company, valued at approximately $7,139,264.40. This represents a 52.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Michael Chi sold 13,750 shares of Hims & Hers Health stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $56.00, for a total transaction of $770,000.00. Following the sale, the insider directly owned 278,654 shares in the company, valued at $15,604,624. The trade was a 4.70% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,448,056 shares of company stock valued at $75,139,240 in the last 90 days. 17.71% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms have commented on HIMS. Wall Street Zen downgraded shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a research note on Monday, July 28th. Weiss Ratings reiterated a "hold (c+)" rating on shares of Hims & Hers Health in a research report on Tuesday, October 14th. Canaccord Genuity Group restated a "buy" rating and set a $68.00 price target on shares of Hims & Hers Health in a research report on Friday, September 12th. Citigroup reiterated a "sell" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Finally, Needham & Company LLC restated a "hold" rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Two equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, Hims & Hers Health has a consensus rating of "Reduce" and an average target price of $38.92.

Hims & Hers Health Stock Up 3.3%

NYSE HIMS opened at $51.40 on Tuesday. Hims & Hers Health, Inc. has a 1 year low of $18.33 and a 1 year high of $72.98. The stock has a market capitalization of $11.62 billion, a PE ratio of 64.25, a PEG ratio of 3.39 and a beta of 2.25. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. The business's 50-day moving average is $51.04 and its 200 day moving average is $49.21.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The business had revenue of $544.83 million during the quarter, compared to analysts' expectations of $550.06 million. During the same quarter last year, the business posted $0.06 EPS. The company's quarterly revenue was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.